Helixmith has made public the topline data of the phase 2a clinical trial of Engensis (VM202), its genetic treatment candidate for amyotrophic lateral sclerosis (ALS).
SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Helixmith Co., Ltd. has announced that 50 subjects have been enrolled in its double-blind placebo controlled COVID-19 clinical trial involving 100 subjects. The investigational product is called TADIOS, which is a proprietary botanical treatment. The clinical trial is being conducted in India in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body. India has a high rate of COVID-19 infection and unmet medical need.
“Patients with DPN experience high levels of pain and discomfort, with no medicine available that treats the underlying disease,” says Miguel Trevino, MD, Medical Director, Innovative Research of West Florida. “REGAiN-1A will inform the ongoing clinical efforts to develop a new potentially regenerative medicine therapy.”